https://www.selleckchem.com/pr....oducts/ccs-1477-cbp-
Finally, we discuss prospects and challenges in the clinical development of pancreatic cancer therapeutics.Triple-negative breast cancer (TNBC) is the most challenging subtype of breast cancer. Various endeavor has been made to explore the molecular biology basis of TNBC. Herein, we reported a novel function of factor Kinectin 1 (KTN1) as a carcinogenic promoter in TNBC. KTN1 expression in TNBC was increased compared with adjacent tissues or luminal or Her2 subtypes of breast cancer, and TNBC patients with high KTN1 expressio
Like
Comment
Share
